openPR Logo
Press release

Preeclampsia Laboratory Testing Market Will Thrive at a Promising 10.2% CAGR Globally, by 2025 : Fairfield Market Research

07-02-2021 09:00 AM CET | Health & Medicine

Press release from: Fairfield Market Research

Preeclampsia Laboratory Testing Market Will Thrive at

Up from revenues worth US$1,242.9 Mn in 2020, the global preeclampsia laboratory testing market will thrive at a promising 10.2% CAGR during 2021 – 2025. A new market intelligence report published by Fairfield Market Research states that in addition to high prevalence of preeclampsia, an improving level of awareness and rate of early diagnosis are driving the growth of market. Blood tests remain preferred over urine tests owing to their accuracy in diagnosis of preeclampsia.

For more insights into the Market, Get a Sample Copy of this Report:
https://www.fairfieldmarketresearch.com/report/preeclampsia-laboratory-testing-market/

Pressing Need for Efficient Preeclampsia Diagnostics to Fuel Market Expansion
While maternal and/or foetal mortality due to undiagnosed and/or untreated preeclampsia can be prevented, awareness will remain instrumental to the market build-up, says the report. There has been notable improvement in awareness about preeclampsia screening during the course of antenatal care, which reflects a strong indication that the market for preeclampsia laboratory testing will witness a progressing trail in long term. Scarce availability of efficient midwives and obstetric healthcare centres amid the current pandemic is resulting in delayed or cancelled cases of abortion. In addition, the number of COVID-19 positive pregnant women is on the rise. This situation raises demand for efficient preeclampsia diagnostics, bolstering the growth of preeclampsia laboratory testing market.

Elevating Health and Economic Burden Raises Scope for Market Growth
While developing economies have been struggling with the rising health and economic burden, the developed world is also facing the similar challenge. In the US alone, preeclampsia is the third leading cause of maternal mortality and the fraction of maternal deaths there is considerable. The medical costs associated with preeclampsia patients and infants born to them are over the odds for general public, as stated by Preeclampsia Foundation. On other hand, in some of the Asian and African countries, about 1 in 10 deaths is associated with hypertension in pregnancy. In a majority of low- and middle-income economies, an average rate of preeclampsia prevalence is 8-10%.

Preeclampsia Laboratory Testing Market Press Release:
https://www.fairfieldmarketresearch.com/oligopolistic-conditions-make-entry-challenging-for-entrants-in-preeclampsia-laboratory-market/

Asia Pacific Remains Potential Hotspot in Preeclampsia Laboratory Testing Market
The regional analysis reveals that North America is spearheading the global market and will demonstrate a robust 9.6% CAGR through 2026. This growth is attributed to the various initiatives in favour of developing and maintaining better diagnostics regimen for preeclampsia.

On the other side, the impact is more severe in developing nations as a result of deficient policy structure, delayed diagnosis and decision making, delayed healthcare access, and lack of proper implementation at micro and macro levels. Players in preeclampsia laboratory testing market thus currently face major obstacles especially in developing regional markets. Fast-developing Asian countries such as China and India have been witnessing higher rates of preeclampsia instances. Asia Pacific will remain a high-potential market for the companies active in preeclampsia laboratory testing market.

In Order to place the Purchase Query Click Here: sales@fairfieldmarketresearch.com

Competition Intensifies with Collaborated R&D Efforts and New Test Introductions
The report provides elaborate strategic insights into some of the most prominent players participating in the global preeclampsia laboratory testing market. ThermoFischer Scientific, F. Hoffmann-La Roche AG, and PerkinElmer, Inc. represent the global market leaders currently accounting for a collective share of more than 60% in the total market revenue. Bayer AG, Sera Prognostics, Inc., Siemens Healthineers AG, Diabetomics, Inc., Metabolomic Diagnostics Ltd., Progenity, Inc., and DRG Instruments GmbH are the other important companies contributing their share towards the growth of preeclampsia laboratory testing landscape.

Over the recent past, launch of new products is trending the competition landscape. In 2019, Diabetomics, Inc. introduced Lumella, a rapid point-of-care (POC) test that identifies the level of risk of developing preeclampsia among pregnant women. The soon-to-commercialise preeclampsia rule-out test launched by Progenity, Inc. is expected to add to the momentum of preeclampsia laboratory testing in the near future. Some pharma players are also focusing on R&D in collaboration with recognised research companies. In 2020, Ferring Pharmaceuticals and Igenomix, S.L. announced a project on the development of novel therapeutic and diagnostic procedures for preeclampsia.

Browse Our Latest Reports : https://www.fairfieldmarketresearch.com/shop/

Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA +1 (844) 3829746 (Toll-free)
Email: mail@fairfieldmarketresearch.com
Follow us on LinkedIn: https://bit.ly/3voYIm9

About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Preeclampsia Laboratory Testing Market Will Thrive at a Promising 10.2% CAGR Globally, by 2025 : Fairfield Market Research here

News-ID: 2319681 • Views:

More Releases from Fairfield Market Research

Soaring Uptake by Dietary Supplements Industry to Favour Omega 3 Market Growth, Says a New Study
Soaring Uptake by Dietary Supplements Industry to Favour Omega 3 Market Growth, …
Global omega 3 market that surpassed the valuation of US$4.4 Bn in the year 2019 is likely to reach the revenue of around US$13 Bn toward the end of 2027. In its latest published report, Fairfield Market Research forecasts a robust 14.6% CAGR for omega 3 market over the period of projection, 2021 - 2027. The growth of fortified foods across international markets and increasing worldwide focus on mother-and-new-born nutrition
Oat Milk Sales Elevate on the Back of Veganism, Dairy-free, Plant-based, and Gluten-free Trends
Oat Milk Sales Elevate on the Back of Veganism, Dairy-free, Plant-based, and Glu …
Exhibiting an estimated CAGR of 11.5%, global oat milk market value is likely to surpass US$2.6 Bn by the end of 2026. As suggested by the latest Fairfield Market Research report, oat milk sales will gain significantly from the thriving plant-based F&B trend. With plant-based, lactose-free, and gluten-free trend waves gathering momentum over the recent past, the nutrition profile of oat milk will continue to drive its demand at household,
Global Narcolepsy Drugs Market to Register a CAGR of 11.2% as Pandemic Brings Attention to Sleep Disorders
Global Narcolepsy Drugs Market to Register a CAGR of 11.2% as Pandemic Brings At …
The global narcolepsy drugs market has been under the spotlight recently as the awareness about sleep disorders grows. The pandemic brought with it a sudden wave of sleeping disorders as many found their daily schedules disrupted. Psychological distress added to the gamut of issues, which has raised awareness about narcolepsy too. As the focus on improving lifestyle in the post-pandemic world continues, analysts at Fairfield Market Research estimate the sentiment
Low Carbon Footprint of Microbial Fuel Cell (MFC) to Create Sustained Demand within the Market
Low Carbon Footprint of Microbial Fuel Cell (MFC) to Create Sustained Demand wit …
The global microbial fuel cell (MFC) market is expected to cross the growth threshold required for competitors to make lucrative gains. The total worth of the global microbial fuel cell (MFC) market is expected to supplant US $15 Mn by the end of 2025, growing at a stupendous CAGR of 9.8% during the period between 2021 and 2025. The wide spectrum of applications pertaining to microbial fuel cells is the

All 5 Releases


More Releases for Preeclampsia

Preeclampsia Diagnostics Market: 2020 Worldwide Opportunities, Market Share, Key …
The study by Fortune Business Insights on the global preeclampsia diagnostics market is titled, "Preeclampsia Diagnostics Market Size, Share & Industry Analysis, By Test Type (Biomarkers, Immunoassays), By Product (Instruments, Consumables), By End-user (Hospitals & Clinics, Maternity Clinics, Diagnostic Centers, Others) and Regional Forecast, 2019-2026." The report provides a comprehensive analysis of the preeclampsia diagnostics market with prime emphasis on trajectories such as growth drivers and restraints, trends and opportunities.
Preeclampsia Diagnostics Market Size, Global Share, Supply, Demand, Segments and …
The global preeclampsia diagnosis market size is projected to reach USD 2,165.0 million by 2026, thereby exhibiting a CAGR of 10.7% during the forecast period. However, the market was valued at USD 969.5 million in 2018. This information is published in a recent study by Fortune Business Insights™, titled, “Preeclampsia Diagnosis Market Size, Share & Industry Analysis, By Test Type (Blood Tests and Urine Analysis), By Product (Instruments and Consumables)
Preeclampsia Diagnostics Market: Analysis, Trends, Opportunity, Market Size and …
Preeclampsia is a hypertensive disorder of pregnancy and affects about 5% of pregnant women globally, out of whom 0.5% to 1% develop it in the severe form. It is one of the most common complication of pregnancy and a major cause of morbidity, long-term debility, and death among both the baby and the mother. Preeclampsia generally occurs after the 20th week of pregnancy, caused by mixture of elevated blood pressure
Preeclampsia Diagnostics Market Size Projected to Rise Lucratively during 2017-2 …
Preeclampsia is a hypertensive disorder of pregnancy and affects about 5% of pregnant women globally, out of whom 0.5% to 1% develop it in the severe form. It is one of the most common complication of pregnancy and a major cause of morbidity, long-term debility, and death among both the baby and the mother. Preeclampsia generally occurs after the 20th week of pregnancy, caused by mixture of elevated blood pressure
Preeclampsia Diagnostics Market Current Trends and Future Aspect Analysis 2017 - …
Preeclampsia is a hypertensive disorder of pregnancy and affects about 5% of pregnant women globally, out of whom 0.5% to 1% develop it in the severe form. It is one of the most common complication of pregnancy and a major cause of morbidity, long-term debility, and death among both the baby and the mother. Preeclampsia generally occurs after the 20th week of pregnancy, caused by mixture of elevated blood pressure
Global Preeclampsia Diagnostics Market Dynamics, Forecast, Analysis and Supply D …
Preeclampsia is a hypertensive disorder of pregnancy and affects about 5% of pregnant women globally, out of whom 0.5% to 1% develop it in the severe form. It is one of the most common complication of pregnancy and a major cause of morbidity, long-term debility, and death among both the baby and the mother. Preeclampsia generally occurs after the 20th week of pregnancy, caused by mixture of elevated blood pressure